Seth Lederman (Insider Trades), CEO of Tonix Pharmaceuticals Holding Corp. (TNXP), bought 6,000 shares of the company on July 17, 2015. The average price per share was $7.50, for a total transaction amount of $45,000. Tonix Pharmaceuticals is a developer of next-generation medicines for common central nervous system disorders. The company's market cap is $140.94 million.
Lederman bought 21,000 shares of Tonix in seven transactions since February 9, 2015. Tonix director Samuel Saks (Insider Trades) also bought 10,000 shares of the company for an average price of $7.50 per share on July 17, 2015. On the same day, Tonix CFO, Leland Gershell (Insider Trades), bought 1,000 shares of the company for an average per share price of $7.50. There have not been any insider sells of the company since 2013. Month end price for the company decreased from around $40 per share in 2012, to about $6 per share in January 2015. This decrease in month end price corresponds to an increase in frequency and volume of insider buys. Only four insider buys of Tonix were made from 2012 to the end of 2014; all four insider buys, a total of 2,551 shares were made in 2013. There were 16 insider buys of the company in the first half of 2015 alone, totaling over 100,000 shares. 
For more information about insider trades of Tonix Pharmaceuticals Holding Corp., click here.
Tonix reported a net loss of $9.68 million, or $0.71 per share in the first quarter of 2015 compared to a net loss of $5.2 million, or $0.59 per share in the first quarter of 2014. The company has three drugs currently in development, and attributed this increased net loss to increased research and development expenses and administrative and corporate development expenses. Lederman stated that having three “large, adequate, and well controlled clinical studies in high-value therapeutic indications simultaneously ongoing” affirms the company’s business model “in a capital-efficient manner.” Tonix also closed a $20.1 million public offering of 2,325,000 shares of common stock on July 17, 2015.
Guru Jim Simons (Trades, Portfolio) (Trades, Portfolio) of Renaissance Technologies LLC, acquired 104,900 shares of Tonix at an average price of $6.49 per share in the first quarter of 2015. For more information about guru transactions of Tonix Pharmaceuticals Holding Corp., click here.
For more stock trades of gurus in real time, visit GuruFocus’ Real Time Picks, a Premium Feature. Not a Premium Member of GuruFocus? Try it free for 7 days here.
